Sopherion Therapeutics

Press Releases

Jan 18 2010		SOPHERION THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR MYOCET IN METASTATIC BREAST CANCER

Mar 18 2009		SOPHERION THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE III STUDY OF MYOCET IN METASTATIC BREAST CANCER

Mar 02 2009		SOPHERION THERAPEUTICS ANNOUNCES APPOINTMENT OF NEW SENIOR EXECUTIVE VICE PRESIDENT FOR CLINICAL AFFAIRS

Feb 18 2009		SOPHERION THERAPEUTICS SECURES $55 MILLION IN SERIES C FUNDING

Feb 02 2009		SOPHERION THERAPEUTICS LLC ANNOUNCES PUBLICATION OF PHASE I/II MYOCET® (NONPEGYLATED LIPOSOMAL DOXORUBICIN) DATA IN ADVANCED BREAST CANCER PATIENTS